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Colorectal carcinoma is one of the leading causes of cancer
mortality in the Western world, with an increasing incidence in
Singapore (Chia et al, 1996; Wingo et al, 1998). The development
of colorectal carcinoma is a multi-step progression with transfor-
mation of the normal colonic epithelium to an adenomatous polyp
and ultimately an invasive cancer (Gryfe et al, 1997). Genetic
alterations that are involved during this progression include the
dysregulation of the K-ras gene and LOH of chromosomes 5q, 17p
and 18q. These chromosomal regions harbour several tumour
suppressor genes: the adenomatous polyposis gene (APC)(5q),
TP53 gene (17p), and the deleted in colorectal cancer (DCC) gene
(18q) (Fearon and Vogelstein, 1990; Gryfe et al, 1997).
Recent independent analyses of chromosome 11q suggest that a
putative tumour suppressor gene or genes located in chromosome
11q22–q24 may be involved in the tumorigenesis of several solid
tumours of diverse cell types, such as tumours of the breast (Carter
et al, 1994; Negrini et al, 1995; Tomlinson et al, 1995), ovary
(Davis et al, 1996; Gabra et al, 1996), stomach (Baffa et al, 1996),
lung (Rasio et al, 1995), cervix (Hampton et al, 1994),
nasopharynx (Hui et al, 1996) and malignant melanoma
(Tomlinson et al, 1993; Herbst et al, 1995; Robertson et al, 1996).
The involvement of this chromosomal region in the tumorigenesis
of colorectal cancer is unclear, with cytogenetic (Konstantinova et
al, 1991; Keldysh et al, 1993) and some molecular studies
(Tomlinson and Bodmer, 1996; Connolly et al, 1999) indicating
losses in this region but with other molecular studies reporting no
significant losses (Koreth et al, 1997). These studies employed
four or fewer loci from the 11q22–23 region, an insufficient
number to establish clearly the regions of 11q deletion in
colorectal carcinogenesis.
In order to confirm whether the chromosomal region 11q22–23
is indeed lost in colorectal carcinoma and also to identify the
regions of loss, we have performed a comprehensive genetic
analysis of chromosome 11q22–q23 in 57 colorectal tumours
using 16 highly polymorphic microsatellite markers. We have
demonstrated that loss of heterozygosity at this chromosomal
region is common in colorectal carcinoma. The critical regions of
LOH defined by this study will be crucial for future work on the
identification of putative tumour suppressor gene(s) by positional
cloning techniques. We have also observed LOH on 11q23 in
tumours from patients with early Dukes’ Stage (A and B),
implying that loss of 11q is an early event in colorectal cancer.
MATERIALS AND METHODS
Samples
Fifty-seven colorectal carcinoma samples and corresponding
normal colonic mucosa were snap-frozen in liquid nitrogen upon
resection and stored at –70° C. Peripheral blood samples were
collected from each of the patients in EDTA tubes and stored at
–70° C. Fifty-five cases were identified histopathologically as
adenocarcinoma, and two cases were mucinous adenocarcinoma.
Four (7.1%) of the patients presented at Dukes’ stage A, 15
(26.8%) were Stage B, 17 (30.4%) were Stage C and 20 (35.7%)
were stage D. The Dukes’ Stage for one patient was unknown.
DNA extraction
Cryostat sections were cut from each of the tumours, stained with
H&E and viewed. The tumours were then trimmed to exclude
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sections of normal colonic mucosa were also viewed to confirm
the exclusion of neoplastic cells. DNA was extracted from tissues
using DNAzol (GIBCO/BRL, USA) according to the manufac-
turer’s instructions. DNA was extracted from frozen whole blood
using sucrose lysis buffer and proteinase K digestion. The
extracted DNA was quantified by spectrophotometry.
Microsatellite analysis
Sixteen microsatellite markers from the chromosomal region
11q22–23 were selected: D11S940, D11S1778, D11S1818,
D11S1340, D11S29, D11S1356, D11S4104, D11S924, D11S4171,
D11S4132, D11S925, D11S4107, D11S1345, D11S1328,
D11S933 and D11S934. Two microsatellite markers from chromo-
some 11p, D11S929 and D11S1344 were selected as controls. The
primer sequences, chromosome localization and frequency of
heterozygosity were obtained electronically from the Genome
Database and the US National Center for Biotechnology
Information (NCBI) database. Polymerase chain reactions (PCR)
were performed in a 10 µ l volume with 100–400 ng of DNA,
125 µ M of each dNTP, 0.5 µ M of each primer, 1.5 mM MgCl2 and
0.2 units of Taq DNA polymerase (Promega, USA). The sense
primer was end-labelled with [γ -33P]dATP (Amersham, USA or
NEN, USA). The PCR conditions were an initial denaturation step
at 94° C for 3 min, 25 cycles of denaturation (1 min at 94° C),
annealing (1 min at 60–67° C), and extension (1 min at 72° C), and
a final extension step (72° C, 7–15 min). Annealing temperatures
were optimized for each primer pair. The PCR products were sepa-
rated on an 8% polyacrylamide sequencing gel and exposed to
X-ray film overnight and also exposed to the CS phosphor screens
(Biorad, USA) for 4–6 h.
Assessment of LOH
DNA quantitation was performed by scanning the exposed CS
phosphor screens with the Molecular Imager (Model GS-250,
Biorad, USA). LOH was determined by quantitation of the signal
intensity of each allele, and comparing the ratios of the intensity of
the alleles from the tumour DNA with that of the constitutional
(normal mucosa or blood) DNA. The difference in allele ratios
between normal and tumour samples was divided by the allele
ratio for the normal sample and a value of over 0.3 was scored as
LOH, as has been previously described by other investigators
studying LOH in this region (Hampton et al, 1994; Negrini et al,
1995; Connolly et al, 1999).
Calculation of allele ratios were determined by the allelic ratio
method as well (Cawkwell et al, 1993), to allow for the compar-
ison of our data with that of Koreth et al (1997). Briefly, the ratio
of alleles was calculated for each normal and tumour sample and
then the tumour ratio was divided by the normal ratio, i.e.
T1:T2/N1:N2, and with a cut-off ratio of 1.5. All samples with
LOH were repeated to confirm the result.
DNA fingerprinting
All samples with microsatellite instability (MI) were subjected to
DNA fingerprinting using the D1S80 microsatellite marker in
order to verify that the normal and tumour samples were from the
same patient and not from unrelated patients. The extracted DNA
11q23 LOH in colorectal cancer 751
British Journal of Cancer (2000) 83(6)  750–755 © 2000 Cancer Research Campaign
Table 1 The frequency of LOH at 16 microsatellite markers on chromosome 11q22–q23 and two
microsatellite markers on chromosome 11p in colorectal carcinoma
Marker Distance from centromere No. with LOH/No. of No. with LOH/No. of
in megabases (min/max)a informative cases informative cases
(%LOH)b (%LOH)c
D11S929 19.38/19.79d 4/33 (12.1) 1/33 (3.0)
D11S1344 35.07/53.57d 8/32 (25.0) 5/32 (15.6)
D11S940 91.97/97.42 9/41 (22.0) 6/41 (14.6)
D11S1778 101.56/105.43 12/44 (27.3) 11/44 (25.0)
D11S1818 104.23/110.40 16/46 (34.8) 15/46 (32.6)
D11S1340 105.13/111.97 16/39 (41.0) 14/39 (35.9)
D11S29 110.64/120.93 15/46 (32.6) 14/46 (30.4)
D11S1356 106.59/108.87, 14/46 (30.4) 14/46 (30.4)
111.30/111.97
D11S4104 112.75/112.75 9/38 (23.7) 7/38 (18.4)
D11S924 113.02/113.02 13/35 (37.1) 12/35 (34.3)
D11S4171 113.14/113.14 13/41 (31.7) 13/41 (31.7)
D11S4132 113.28/113.28 7/37 (18.9) 6/37 (16.2)
D11S925 113.41/115.23, 14/43 (32.6) 13/43 (30.2)
115.62/115.62
D11S4107 113.54/113.60 17/42 (40.5) 15/42 (35.7)
D11S1345 117.40/117/40, 6/43 (14.0) 5/43 (11.6)
118.32/118.60
D11S1328 118.92/119.09, 9/41 (22.0) 8/41 (19.5)
119.58/119.58
D11S933 119.19/121.31 7/27 (25.9) 6/27 (22.2)
D11S934 120.21/121.31 11/33 (33.3) 10/33 (30.3)
aThe distance from the centromere was obtained from the Genome Database (http//:gdbwww.gdb.org);
bAssessment of LOH using the 30% cutoff as previously described (Hampton et al, 1994; Negrini et al, 1995;
Koreth et al, 1997); cAssessment of LOH using the 50% cutoff as previously described (Cawkwell et al, 1993;
Connolly et al, 1999); dDistance from the centromere on chromosome 11p752 AS-G Lee et al
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was amplified by PCR, as described above, except that end-
labelling with [γ -33P]dATP was not done. The PCR products were
run on a 3% Metaphor (FMC, USA) agarose gel to determine the
sizes of the products.
Statistical analysis
The Fisher’s exact test and Chi-squared test were used to deter-
mine any associations between LOH and clinicopathological
parameters. Information on Dukes’ stage was available for 56 of
the 57 patients.
RESULTS
Table 1 shows the frequency of loss of heterozygosity (LOH) in
the 57 colorectal carcinomas. The results of microsatellite
analyses for all samples are shown in Table 2. Table 3 shows the
correlation of clinicopathological parameters and presence or
absence of LOH. Representative examples of LOH and
microsatellite instability (MI) are shown in Figures 1 and 2
respectively.
To determine the prevalence of LOH and MI on chromosome
11q22–q23 in colorectal carcinoma, 16 highly polymorphic
microsatellite markers spanning this region were utilized to
compare the tumour DNA and corresponding normal DNA from
57 colorectal carcinoma patients. Enrichment of neoplastic cells
was achieved by the cryosectioning technique in order to reduce
the proportion of contaminating non-neoplastic cells which would
reduce or mask the observation of LOH. Accurate assessment of
LOH was derived from direct measurement of signal intensities of
each allele using phosphor screens and a molecular imager.
This study has defined three markers with frequent LOH,
D11S1340 (41.0%), D11S924 (37.1%) and D11S4107 (40.5%),
using the 30% cutoff value (Table 1). D11S1340 is located
105.13–111.97 Mb from the centromere. Both D11S924 and
D11S4107 are located approximately 113 Mb from the centromere
on the long arm of chromosome 11 (Table 1). The lowest
frequency of LOH at the 11q23 region was at D11S1345 with a
frequency of 14.0% (Table 1). The frequency of LOH on the short
arm of chromosome 11 was 12.1% at D11S929 (11p14), and 25%
at D11S1344 (11p11–12).
Overall, 36 of the 57 colorectal cases (63.2%) showed LOH
for at least one marker on chromosome 11q22–q23 (Table 2).
LOH was calculated using 0.3 as the cutoff value (Hampton et al,
1994; Negrini et al, 1995; Connolly et al, 1999). A complex
pattern of LOH was observed in this series of tumours, with
regions exhibiting allelic losses interspersed with regions where
heterozygosity was retained (Table 2), and this is likely to be
caused by the different underlying genetic mechanism of allele
loss. Three cases, 55, 33 and 47, showed probable chromosomal
non-disjunction, consistent with loss of the entire chromosome
11, with either LOH or homozygosity observed at all microsatel-
lite markers (Table 2). Terminal deletion was observed in eleven
cases (34, 44, 31, 59, 11, 33, 47, 35, 69, 70, and 65) (Table 2).
Interstitial allele loss caused by mitotic recombination, deletion
or gene conversion was observed in the majority of the remaining
cases with LOH and have become apparent in this study due to
the large number of microsatellite markers used to examine the
frequency of LOH.
Microsatellite instability (MI) is depicted by numerous or aber-
rant alleles at a microsatellite locus indicating genomic instability.
Microsatellite instability was detected in 11 (19.3%) of 57
colorectal carcinoma samples and was detected at all the
microsatellite markers except for D11S924 (Table 2). This
frequency of MI is similar to that of other studies of MI in sporadic
colorectal cancer (Risio et al, 1996; Gryfe et al, 1997). Six tumours
displayed MI at only one of the markers and five tumours had MI
at two or more markers, suggesting the involvement of mismatch
repair genes in the development of these tumours (Table 2).
Representative examples of MI are shown in Figure 2. DNA
fingerprinting with the D1S80 marker was done on all these 11
cases with microsatellite instability and showed that the normal
and tumour DNA for these patients were matched and not from
different individuals.
No associations were seen between the presence of LOH and
Dukes’ stage or the patient’s age at diagnosis (Table 3). LOH was
detected in one of four (25.0%) cases at Dukes’ stage A, 10 of 15
(66.7%) cases at stage B, 13 of 17 cases at stage C (76.5%) and 10
of 20 (50.0%) cases at stage D (Table 3).
DISCUSSION
This is the first paper describing a detailed deletion mapping of the
chromosome 11q22–q23 region in colorectal carcinoma, utilizing
16 microsatellite markers to this region. The highest frequencies of
LOH were observed at D11S1340 (41.0%), located 105.13–111.97
Mb from the centromere, and at D11S924 (37.1%) and D11S4107
(40.5%), both located approximately 113 Mb from the centromere.
These two regions were bordered by microsatellite markers
showing lower frequencies of LOH. All markers (D11S924,
D11S4171, D11S925, D11S4107) located approximately 113 Mb
from the centromere had frequencies of LOH above 30% with the
exception of one marker, D11S4132, which could possibly be due
to inaccurate chromosomal localization. This study has further
refined the region of LOH on 11q23, with our data suggesting the
possibility of two defined regions of loss, rather than one regionspanning 4.9 Mb, between D11S897 and D11S925 as reported by
Connolly et al (1999).
Previous RFLP and microsatellite analyses of the chromosomal
region 11q22–q23 in colorectal carcinoma have only utilized
between one to four loci, with conflicting data on the frequency of
loss of heterozygosity (LOH). Koreth et al (1997) reported a low
frequency of LOH of 11–12% in this area, utilizing two microsatel-
lite markers to this region, D11S35 and D11S29. Moderate levels of
LOH were obtained at the D11S29 locus (29%) and the dopamine
D2 receptor locus (33.8%) in two other studies (Gustafson et al,
1994; Tomlinson and Bodmer, 1996). By employing RFLP
methods and studying only four loci at this chromosomal region,
Keldysh et al (1993) detected LOH at a high frequency of 50–60%
in the same chromosomal region. Recently, high frequencies of
LOH of 40% and 47.6% were reported by Connolly et al (1999), in
their study employing two microsatellite markers in this region,
D11S897 and D11S925. Our findings of high frequencies of LOH
provides further evidence that the chromosomal region 11q23 is
indeed lost during colorectal carcinogenesis.
Variations in the frequencies of LOH between studies of the
same tumour type and using the same microsatellite marker may
be due to the different cutoff criteria used for the assessment of
LOH. In order to compare our microsatellite analysis with those
from other studies, we have reported the LOH frequency using the
30% cutoff value (Hampton et al, 1994; Negrini et al, 1995;
Connolly et al, 1999) and the 50% cutoff value (Cawkwell et al,
1993; Koreth et al, 1997) (Table 1). We note a general reduction of
%LOH using the 50% cutoff criteria, described by Cawkwell et al
(1993). Using the 30% cutoff, LOH at D11S925 was observed in
47.6% of cases analysed by Connolly et al (1999) but in only
32.6% of our cases. Nevertheless, these values are higher than that
reported by Koreth et al (1997) at D11S29 of 12%, which was
assessed using the 50% cutoff. A similar analysis of this same
marker, D11S29, in our case showed LOH of 30.4%. However, we
conclude that either criteria may be used to define the frequencies
of LOH within a study, as both criteria allow the identification of
high LOH rates in relation to LOH rates observed at other markers
in that study. The highest rates of LOH in this study, at D11S1340,
D11S924 and D11S4107, were observed at the same markers, for
both cutoff values. Reporting of LOH frequency using both criteria
may be helpful for comparisons between studies.
By utilizing an extensive panel of microsatellite markers in this
study, we have excluded the possibility of these losses being a
reflection of generalized chromosomal instability. The low
frequency of LOH on the short arm of chromosome 11 at D11S929
was similar in frequency to that at D11S1345, on 11q. In contrast,
higher frequencies of LOH were observed at the D11S1340,
D11S924 and D11S4107 on 11q23.
The D11S1340 locus is located approximately 105.13–111.97
Mb from the centromere. Also located in this region is the
recently identified putative tumour suppressor gene, PPP2R1B,
which encodes the β isoform of the A subunit of the serine/
threonine protein phosphatase (PP2A). PP2A has been linked to
11q23 LOH in colorectal cancer 753
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Table 3 LOH and clinicopathological parameters
LOH No  LOH Statistical P
(%) (%) test
Age at presentation Fisher’s exact test 0.163
≤ 50 years 10 (79.9) 3 (23.1)
> 50 years 25 (56.8) 19 (43.2)
Dukes’ Stage Chi-squared test by exact method 0.156
A 1 (25.0) 3 (75.0)
B 10 (66.7) 5 (33.3)
C 13 (76.5) 4 (23.5)



















Figure 1 Examples of LOH on chromosome 11 in representative colorectal
carcinoma samples. Top = case numbers; Left = microsatellite markers listed
from the most centromeric to the most telomeric; N = normal; T = tumour.
Shown at the bottom of each autoradiograph is D, the difference in allele
ratios between normal and tumour samples, divided by the allele ratio for the
normal sample. When the allele ratio in tumour DNA differed more than 30%
from the ratio of alleles in normal DNA, LOH was scored. Arrowheads
indicate the allele lost in tumour DNA754 AS-G Lee et al
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carcinogenesis, is involved in the down-regulation of the
mitogen-activated protein kinase cascade and relays signals for
cell proliferation. Alterations of the PPP2R1B gene were detected
in human lung and colon cancer (Wang et al, 1998). This gene
was identified from a region exhibiting high frequency of LOH of
42.9% and 46.2% respectively, using the D11S1647 and
D11S1987 loci (Wang et al, 1998).
Both the loci D11S924 and D11S4107 are located approxi-
mately 113 Mb from the centromere. Deletions in this region have
been detected in tumours of the nasopharynx (Hui et al, 1996),
cervix (Hampton et al, 1994), ovary (Gabra et al, 1996), breast
(Negrini et al, 1995) and lung (Rasio et al, 1995). Other genes
located in this region include the CBL gene which participates in
the signal transduction of haematopoietic cells (Blake et al, 1991)
and the MLL gene which is translocated in acute leukaemias and
possibly acts as a transcriptional regulatory factor (Gu et al, 1994).
Other possible candidate genes include the LOH11CR2A gene that
has been molecularly cloned (Monaco et al, 1997) and the BRCA3
gene which has been associated with the constitutional transloca-
tion 11q;22q (Iselius et al, 1983; Lindblom et al, 1994).
We have observed LOH on 11q23 in colorectal tumours from
patients with Dukes’ stage A (25%) and B (67%), suggesting that
loss of function of a tumour suppressor gene on 11q23 occurs in
the early stages of colorectal cancer. This finding is consistent with
those of Evans et al (1998) and Davis et al (1996) who have
reported that 11q deletion occurs early in cervical and ovarian
neoplasia.
Our study has confirmed that LOH on chromosome 11q23 plays
an important role in the pathogenesis of colorectal cancer. The two
regions of deletion defined here suggest the presence of at least
two putative tumour suppressor genes on 11q23 and will facilitate
the identification of candidate tumour suppressor genes from this
region.
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